HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clark, W. F. Articles by Parbtani, A. Search for Related Content PubMed PubMed Citation Articles by Clark, W. F. Articles by Parbtani, A.

Flaxseed in Lupus Nephritis: A Two-Year Nonplacebo-Controlled Crossover Study

London Health Sciences Centre, Westminster Campus, The University of Western Ontario, London, Ontario, CANADA

Address reprint requests to: Dr. William F. Clark, London Health Sciences Centre, Westminster Campus, The University of Western Ontario, London, Ontario, N6A 4G5, CANADA. E-Mail: william.clark{at}lhsc.on.ca

Objective: The objective of this study was to determine the renoprotective effects of ground flaxseed in patients with lupus nephritis.

Methods: Forty patients with lupus nephritis were asked to participate in a randomized crossover trial of flaxseed. Twenty-three agreed and were randomized to receive 30 grams of ground flaxseed daily or control (no placebo) for one year, followed by a twelve-week washout period and the reverse treatment for one year. At baseline and six month intervals, serum phospholipids, flaxseed sachet counts, serum creatinine, 12-hour urine albumin excretion and urine albumin to creatinine ratios, serum viscosity and plasma lipids were measured.

Results: There were eight drop-outs and of the 15 remaining subjects flaxseed sachet count and serum phospholipid levels indicated only nine were adherent to the flaxseed diet. Plasma lipids and serum viscosity were unaltered by the flaxseed supplementation whereas serum creatinine in the compliant patients during flaxseed administration declined from a mean of 0.97±0.31 mg/dL to a mean of 0.94±0.30 mg/dL and rose in the control phase to a mean of 1.03±0.28 mg/dL [p value <0.08]. Of the fifteen patients who completed the study, similar changes were noted [p value <0.1]. The nine compliant patients had lower serum creatinines at the end of the two-year study than the 17 patients who refused to participate [p<0.05]. Microalbumin at baseline declined in both control and flaxseed time periods, but there was a trend for a greater decline during flaxseed administration [p<0.2].

Conclusions: Flaxseed appears to be renoprotective in lupus nephritis, but this interpretation is affected by under powering due to poor adherence and potential Hawthorne effects.

Key words: systemic lupus erythematosus, lupus nephritis, flaxseed, renal outcomes, adherence

This article has been cited by other articles:

				L. T. Bloedon, S. Balikai, J. Chittams, S. C. Cunnane, J. A. Berlin, D. J. Rader, and P. O. Szapary Flaxseed and Cardiovascular Risk Factors: Results from a Double Blind, Randomized, Controlled Clinical Trial J. Am. Coll. Nutr., February 1, 2008; 27(1): 65 - 74. [Abstract] [Full Text] [PDF]

				A. Kilkkinen, I. Erlund, M. J. Virtanen, G. Alfthan, K. Ariniemi, and J. Virtamo Serum Enterolactone Concentration and the Risk of Coronary Heart Disease in a Case-Cohort Study of Finnish Male Smokers Am. J. Epidemiol., April 15, 2006; 163(8): 687 - 693. [Abstract] [Full Text] [PDF]

				C. Stuglin and K. Prasad Effect of Flaxseed Consumption on Blood Pressure, Serum Lipids, Hemopoietic System and Liver and Kidney Enzymes in Healthy Humans Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 23 - 27. [Abstract] [PDF]